Quick Facts
| Property | Value |
|---|---|
| Category | Experimental Fat-Targeting Peptide |
| Risk Level | Experimental |
| Administration | Subcutaneous Injection |
| Typical Frequency | Daily |
| Estimated Half-Life | Limited Human Data Available |
| Primary Research Interest | Targeted Fat Loss / Adipose Tissue Reduction |
This material is provided strictly for educational and informational purposes related to experimental compounds and peptide research. Adipotide is not approved for general human use and carries potentially significant health risks. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 250 mcg = 0.075 mL (7.5 units)
2. Route of Administration
Adipotide has most commonly been discussed in experimental settings as a subcutaneous injectable compound.
- Primary Route: SubQ Injection
- Preferred Timing: Morning administration
- Administration Notes: Frequently discussed in fasted-state protocols
3. Typical Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 250 mcg (7.5 units) daily for 2 weeks, increasing by 250 mcg every 2 weeks as tolerated
- Frequency: Daily, preferably in the morning while fasted
- Cycle Length: 8 weeks on / 16 weeks off
- Special Notes: None provided
4. Summary
Adipotide is an experimental peptide compound originally investigated for its potential to selectively target blood vessels supplying white adipose tissue.
Research interest focused primarily on fat reduction and metabolic effects through targeted disruption of adipose-associated vasculature.
5. Mechanism of Action
Adipotide functions through a targeted peptide-drug approach designed to bind receptors associated with adipose tissue vasculature.
After binding targeted blood vessel markers, the compound was designed to induce apoptosis within blood vessels supplying fat tissue, theoretically reducing adipose tissue survival and storage capacity.
6. Potential Benefits
- Targeted adipose tissue reduction
- Potential decreases in body fat percentage
- Possible improvements in metabolic markers
- Potential reductions in waist circumference
- Non-stimulant experimental fat-loss mechanism
7. Potential Risks / Side Effects
Experimental
- Kidney stress concerns
- Dehydration risk
- Fatigue
- Nausea
- Electrolyte imbalance concerns
- Unknown long-term organ effects
- Potential vascular complications
- Limited human safety data
8. Half-Life
Reliable human pharmacokinetic data for Adipotide remain limited.
Most available information originates from animal studies and experimental discussions rather than extensive clinical use.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Kidney disease or impaired renal function
- Cardiovascular disease
- Pregnancy or breastfeeding
- Electrolyte imbalance disorders
- Underlying metabolic instability
11. Research References
- PubMed
- NIH Publications
- Experimental obesity research literature
- Peer-reviewed vascular targeting studies
CKF Tide Tables 